# Iovance Biotherapeutics financial performance and stock rise > Live situation record from CLSTR: https://clstr.news/situations/iovance-biotherapeutics-financial-performance-and-stock-rise > Updated: 2026-08-15T19:36:40.000Z. Sources: 4. Developments: 2. Iovance Biotherapeutics experienced significant financial growth and stock market momentum in mid-2026. The company reported second-quarter revenue of approximately $99.3 million, representing a 66% increase from the previous year and exceeding analyst expectations. This growth was largely attributed to $91 million in U.S. sales of its cell therapy, Amtagvi, for advanced melanoma. Following these results, the company’s stock saw an initial surge of over 30%. By mid-August, the shares had rallied more than 130% year-to-date, approaching 52-week highs. While technical indicators showed a strong bullish trend with prices remaining above key moving averages, analysis also noted the stock might be in overbought territory due to a high Relative Strength Index. By August 15, 2026, the stock reached a 52-week high, closing at $6.98. This rally followed record revenue for Amtagvi and improved gross margins in the second quarter. Despite the upward momentum, technical indicators such as the RSI continued to suggest overbought conditions. ## Timeline ### 2026-08-15: Iovance Biotherapeutics surges as institutional investors shift Qualcomm and Atkore holdings Iovance Biotherapeutics shares have surged over 130% in 2026 following record revenues, while institutional investors adjust positions in Qualcomm and Atkore Inc. 4 sources. https://clstr.news/cluster/iovance-biotherapeutics-stock-rallies-over-130-in-2026 ### 2026-08-06: Iovance Biotherapeutics Shares Surge Over 30% on Record Q2 Revenue Iovance Biotherapeutics posted a record $99.3 M Q2 revenue, up 66%, prompting a 34% stock surge; the gain follows strong Amtagvi sales and a review of full‑year guidance. 3 sources. https://clstr.news/cluster/iovance-biotherapeutics-shares-surge-over-30-on-record-q2-revenue --- Cite as: Iovance Biotherapeutics financial performance and stock rise. CLSTR, https://clstr.news/situations/iovance-biotherapeutics-financial-performance-and-stock-rise